Clinical Trial Search

N/A N=71 Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment

Late Onset Alzheimer

Primary: Cognitive Response After Three Months of Treatment With ChEI in Mild and Moderate Alzheimer's Disease — 19; 11.3; 18.9; 11.5 units on a scale

Federal University of Minas Gerais Results Jun 2018 0.0% serious AE View details

Phase 3 N=248 A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

Primary: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Average of Week 4 and Week 8 — -0.3; 4.4; 6.5 percentage of…

Vertex Pharmaceuticals Incorporated Results Jun 2018 6.7% serious AE View details

Phase 3 N=168 A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12 — -0.1; 1 Percentage of predicted FEV1 — p== 0.1176

Vertex Pharmaceuticals Incorporated Results Jun 2018 14.9% serious AE View details

Phase 2 N=12 Study of Clinical Efficacy and Safety of Tosedostat in MDS

Myelodysplastic Syndrome

Primary: Over All Survival — 15.9 months

Weill Medical College of Cornell University Results Jun 2018 66.7% serious AE View details

N/A N=2,060 The Louisiana (LA) Health Project

Childhood Obesity

Primary: % Body Fat (Boys) — -1.3; -2.0; -0.11 percentage of body fat

Pennington Biomedical Research Center Results Jun 2018 0.0% serious AE View details

Phase 3 N=3,527 This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

Urinary Bladder Overactive · Urinary Bladder Diseases\Urologic Diseases · Overactive Bladder

Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.34; -1.70; -1.76; -1.79 incontinence episodes — p=0.072

Astellas Pharma Europe B.V. Results Jun 2018 1.6% serious AE View details

Phase 2 N=92 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Renal Cell Carcinoma

Primary: Best Response by RECIST v1.0 — 0; 1; 0; 1 Participants

Idera Pharmaceuticals, Inc. Results Jun 2018 31.5% serious AE View details

Phase 2 N=130 Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

Corneal Epithelial Disorders

Primary: Number of Participants With Clearing of Corneal Fluorescein Staining at Week 5 at Week 5 — 5; 7; 12 Participants

Senju Pharmaceutical Co., Ltd. Results Jun 2018 0.8% serious AE View details

Phase 2 N=3 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

AIDS-Related Plasmablastic Lymphoma · AIDS-Related Primary Effusion Lymphoma · Ann Arbor Stage I Diffuse Large B-Cell Lymphoma

Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants

National Cancer Institute (NCI) Results Jun 2018 50.5% serious AE View details

N/A N=150 Chalazion Conservative Treatment Trial

Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid

Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants

McMaster University Results Jun 2018 0.0% serious AE View details

Phase 2 N=304 Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers

Pneumonia, Pneumococcal

Primary: Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination — 15; 15; 18; 16 Participants

PATH Results Jun 2018 5.6% serious AE View details

Phase 2 N=96 American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial

HIV/AIDS-associated Fatigue

Primary: Change in Fatigue Severity Score (FSS) — -24.7; -16.3; -16.9; -21.6 units on a scale — p=0.15

Johns Hopkins University Results Jun 2018 10.4% serious AE View details

Phase 3 N=210 Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes

Renal Cancer

Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR

Memorial Sloan Kettering Cancer Center Results Jun 2018 15.1% serious AE View details

Phase 2 N=37 A Study of Muscle Strength Maintenance in Older Adults

Sarcopenia

Primary: Change From Baseline in Isokinetic Strength — -4.90; -4.73 Newton — p=0.97

Johns Hopkins University Results Jun 2018 2.7% serious AE View details

N/A N=35 The Effectiveness of SensAwake™ for Continue Positive Airway Pressure Treatment of Obstructive Sleep Apnea Patients

Obstructive Sleep Apnea

Primary: Compliance of Auto-CPAP Therapy — 41.8; 39.7 percentage of nights

Chang Gung Memorial Hospital Results Jun 2018 0.0% serious AE View details